PRAX · Praxis Precision Medicines, Inc
$252.96
-2.30% last session
End-of-day data · close of 2026-10-23
Market cap
$7B
Enterprise value
$6B
Trailing P/E
—
Forward P/E
-26.6
Dividend yield
0.0%
Beta
2.81
Avg volume
0M
Employees
0K
Daily Change %
-2.30%
5 Days Change
7.10%
10 Days Change
6.40%
30 Days Change
-8.22%
60 Days Change
-29.65%
Month to Day Change
-9.76%
Year to Day Change
-12.15%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — PRAX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-16
Latest call per bank · past 12 months
JP Morgan
Overweight$700
+176.7% vs priceUBS
Buy$706
+179.1% vs priceGoldman Sachs
Buy$575
+127.3% vs priceRBC Capital
Outperform$462
+82.6% vs priceWells Fargo
Equal-Weight$362
+43.1% vs priceDeutsche Bank
Buy$374
+47.8% vs priceJefferies
Buy$450
+77.9% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-16 | JP Morgan | Initiates | Overweight | $0.00 → $700 |
| 2026-10-15 | UBS | Initiates | Buy | $0.00 → $706 |
| 2026-10-15 | HC Wainwright & Co. | Reiterates | Buy | $1,201 |
| 2026-10-06 | HC Wainwright & Co. | Reiterates | Buy | $1,201 |
| 2026-10-06 | BTIG | Maintains | Buy | $810 → $826 |
| 2026-09-24 | HC Wainwright & Co. | Reiterates | Buy | $1,201 |
| 2026-09-24 | Needham | Reiterates | Buy | $582 |
| 2026-08-21 | Goldman Sachs | Maintains | Buy | $470 → $575 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 38 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 18.6% below the 50-day MA ($310.66).
- bearish: Price vs 200-day MA: Trading 19.7% below the 200-day MA ($315.05).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+2.19) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($164.09) and high ($386.33).
PRAX Price Chart
Loading chart for PRAX…
Fundamentals
About Praxis Precision Medicines, Inc
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and research collaboration and license agreement to develop an iontophoretic transdermal patch for the delivery of ulixacaltamide. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.